Since our founding in 2001, we have had one singular obsession: We strive to give our clients a personalized and collaborative research experience.

We are here to help you find the answers you need to develop the best possible drug candidate for treating patients with cancer and other diseases.


Discovering Answers through Preclinical Research

Since 2001 we are passionate about offering contract research
to support the drug discovery community.

Company Facts


Clients worldwide


Research projects annually


Data points per year


Publication citations


Patent citations

  • Founded in 2001 in Malvern, Pennsylvania, Reaction Biology was created to provide outstanding kinase-based drug discovery to labs worldwide.
  • We have quickly become the go-to CRO for kinase screening and holding true to our promise for high-quality data and support we have continuously developed assays for new target classes. 20 years later, we offer thousands of assays and a platform for integrated drug discovery.
  • With a second research location in Germany (former ProQinase GmbH), a global business development team and collaborators we have truly become a leading CRO for drug discovery in the world.
  • Research Facilities
  • Business Development Representatives
  • Collaborators
  • Research Facilities
  • Business Development Representatives
  • Collaborators

Preclinical Drug Discovery Platform

Reaction Biology’s team of PhD scientists will take your drug discovery project from target validation through hit identification and hit to lead phases and provide lead optimization studies either on a fee-for-service basis or as integrated partner.

Drug Discovery Process Target Validation Assay Development High-throughput Screening, SAR MedChem Support Potency Selectivity Mechanism of Action ADME & Safety Proof of Concept Studies

The CBC Network

We are proud to be part of the Chemical Biology Consortium (CBC) in the NCI Experimental Therapeutics (NExT) Program, which brings together chemical biologists and molecular oncologists from government, industry, and academia to create new cancer medicines in epigenetic, kinase, and other areas.

As a Specialized Center, we provide uniquely focused technologies that facilitate the successful progression of NExT discovery projects at specific discovery stages.

  • Beryllium Discovery Corp. (UCB)
  • University of California, San Francisco
  • Evotec Compound Management
  • SRI International
  • Sanford Burnham Prebys Medical Discovery Institute
  • The Scripps Research Institute
  • Vala Science Inc.
  • SAMDI Tech
  • Torrey Pines Institute for Molecular Studies
  • University of New Mexico
  • Arizona State University
  • Purdue University
  • University of Pittsburgh
  • Southern Research Institute
  • Albany Molecular Research Inc.
  • Xtal Bio Structures Inc.
  • Pharmaron
  • Reaction Biology Corp.
  • NCATS Chemical Genomics Center
  • University of North Carolina at Chapel Hill
  • Vanderbilt University
  • Emory University
  • University of Chicago